Halozyme Therapeutics (HALO) Retained Earnings (2010 - 2026)

Halozyme Therapeutics (HALO) has 17 years of Retained Earnings data on file, last reported at -$12.7 million in Q1 2026.

• On a quarterly basis, Retained Earnings fell 102.66% year-over-year to -$12.7 million in Q1 2026; TTM through Mar 2026 was -$12.7 million, a 102.66% decrease from a year earlier, with the FY2025 full-year figure at $54.8 million, up 1330.82% from the prior year.
• Retained Earnings for Q1 2026 stood at -$12.7 million, down from $54.8 million in the prior quarter.
• Over the last five years, Retained Earnings for HALO reached as high as $502.1 million in Q3 2025 and fell as low as -$28.4 million in Q2 2025.
• Historically, Retained Earnings has averaged $68.7 million across 5 years, with a median of $24000.0 in 2023.
• Across the five-year window, Retained Earnings plunged 13014.29% in 2022 and surged 697287.5% in 2024, its largest moves.
• Year by year, Retained Earnings stood at -$922000.0 in 2022, then slumped by 906.29% to -$9.3 million in 2023, then jumped by 141.27% to $3.8 million in 2024, then surged by 1330.82% to $54.8 million in 2025, then plunged by 123.19% to -$12.7 million in 2026.
• Per Business Quant data, the three most recent Retained Earnings figures were -$12.7 million in Q1 2026, $54.8 million in Q4 2025, and $502.1 million in Q3 2025.